Efficacy of Third-Line Therapy Using Bevacizumab in a Patient with Metastatic Colorectal Cancer

Gaulin, J; Kotb, Rami; Turcotte, Éric; Bérard, Ghislain; Sawan, Bassem; Schmutz, G; Beauregard, Patrice

doi:10.3747/co.v16i5.395

Cited by 2 publications

(1 citation statement)

References 16 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bevacizumab usually has been administrated with FOLFIRI or FOLFOX as first line chemotherapy in patients with CCLM and a poor prognosis, in the hope of obtaining its additive effect [ 7 - 9 ]. However, some reports have shown usefulness of bevacizumab-containing therapy for advanced colorectal cancer patients after failure of irinotecan, oxaliplatin and cetuximab [ 10 - 13 ]. Results from these reports led us to choose a combination of FOLFOX6 plus bevacizumab as the fourth line chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

Possibility of sandwiched liver surgery with molecular targeting drugs, cetuximab and bevacizumab on colon cancer liver metastases: a case report

et al. 2012

View full text Add to dashboard Cite

A 31-year-old man with sigmoid colon cancer with concomitant simultaneous multiple liver metastases had received FOLFIRI (leucovorin, fluorouracil and irinotecan) and FOLFOX6 (leucovorin, fluorouracil and oxaliplatin) after an ordinary sigmoidectomy. However, his serum carcinoembryonic antigen (CEA) level increased rapidly during the fifteen months after the operation while he was on FOLFOX6. Abdominal computed tomography revealed expanding multiple liver tumors. As the third line chemotherapy, a combination therapy of cetuximab with irinotecan was given, which markedly reduced his levels of serum CEA, and the size and number of liver tumors. He underwent lateral segmentectomy of the liver and microwave coagulation of the liver metastases in the remnant liver. Thereafter, a good quality of life with tumor dormancy was obtained for 6 months. However, his serum CEA started to rise again in the absence of liver tumors. Therefore, FOLFOX6 with bevacizumab was chosen as the fourth line chemotherapy, and the serum CEA was reduced with tumor dormancy. A good quality of life was obtained again at 3 years after the first surgery. This report indicates the effectiveness of sandwiched liver surgery with the molecular targeting drugs cetuximab and bevacizumab on multiple liver metastases of colon cancer, and suggests the possibility of a regimen consisting of bevacizumab following cetuximab.

show abstract